Chiesi's Bronchitol (mannitol) Inhalation Powder Receives the US FDA's Approval for Cystic Fibrosis
Shots:
- In the three large-scale global clinical trials assessing Bronchitol in 761 patients- sustained improvement in FEV1 (Forced Expiratory Volume) with Bronchitol use vs. control group was observed
- Bronchitol is currently approved and marketed in Australia- Italy- Germany- Russia- and several other countries. Additionally- the company anticipates launching Bronchitol in the US in Mar 2021
- Bronchitol (mannitol) inhalation powder is a sugar alcohol and also the 1st and only inhaled dry powder indicated as add-on maintenance therapy to improve pulmonary function in CF patients aged 18 yrs. of age and older
Ref: PRNewswire | Image: StraitTimes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
